SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024
NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 8, 2023 and November 28, 2023.
If you suffered a loss on your investment in Eagle Pharmaceuticals, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Eagle Pharmaceuticals includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company was experiencing slower-thananticipated pull-though from a wholesale customer predominantly due to expiry of inventory; (2) that, as a result, the Company had overstated its revenue; (3) that the Company did not have effective internal controls and procedures over financial reporting as to sales of PEMFEXY, Eagle Pharmaceuticals' metabolic inhibitor product; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: February 9, 2024
Aggrieved Eagle Pharmaceuticals investors only have until February 9, 2024 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-law-offices-of-vincent-wong-remind-eagle-pharmaceuticals-investors-of-a-lead-plaintiff-deadline-of-february-9-2024-302050122.html
SOURCE The Law Offices of Vincent Wong
Ausgewählte Hebelprodukte auf Eagle Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eagle Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Eagle Pharmaceuticals Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Eagle Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Eagle Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.11.18 | Eagle Pharmaceuticals Neutral | Cantor Fitzgerald | |
| 21.03.18 | Eagle Pharmaceuticals Underperform | Mizuho | |
| 09.11.17 | Eagle Pharmaceuticals Outperform | RBC Capital Markets | |
| 06.09.17 | Eagle Pharmaceuticals Underperform | Mizuho | |
| 27.07.17 | Eagle Pharmaceuticals Outperform | RBC Capital Markets |
